NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug NeuroSense Therapeutics Ltd. has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K…
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer, Strengthening Leadership Amid Growth Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing new therapeutic approaches for cardiovascular…
Kairos Pharma Publishes Breakthrough on Overcoming Drug Resistance in NSCLC Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, has announced a significant breakthrough in addressing drug resistance to EGFR-targeted therapies for…
InnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China InnoCare Pharma, a leading biopharmaceutical company dedicated to developing innovative treatments for cancer and autoimmune diseases,…
BPGbio to Present Novel E2-Based TPD Program at 5th Annual Summit BPGbio, Inc., a leading biology-first, AI-powered, clinical-stage biopharmaceutical company focused on mitochondrial biology and protein homeostasis, has announced its…
Optum Rx to Modernize Pharmacy Payment Models Rising drug prices set by pharmaceutical manufacturers are placing significant financial strain on pharmacies across the United States. As the cost of prescription…
MiNA Therapeutics Adds Norbert Bischofberger to Board, Bríd Ryan as CSO MiNA Therapeutics Limited, a leader in the development of small activating RNA (RNAa) therapeutics, has announced key leadership changes…
Triastek announced that on February 27, 2025, its proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product, T20G, received Investigational New Drug (IND) clearance from the U.S. Food and Drug…
ICON Fully Integrates Medidata Clinical Data Studio Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry, has announced a significant partnership…
Scholar Rock Presents Comprehensive Phase 3 SAPPHIRE Trial Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Scholar Rock, a late-stage biopharmaceutical company committed to advancing groundbreaking treatments…
Faeth Therapeutics & GOG-F Launch Phase 2 Trial for Sapanisertib-Serabelisib in Endometrial Cancer Faeth Therapeutics (Faeth), a clinical-stage biotechnology company dedicated to pioneering novel metabolism-based therapeutic strategies, and The GOG…
Biote Announces Fourth Quarter and Full-Year 2024 Financial Results Biote, a leading provider of personalized hormone optimization and therapeutic wellness solutions, has released its financial results for the fourth quarter…
